Form 4: QuidelOrtho CLO Nathaniel Sisitsky Receives Equity Grant
Statement of Changes in Beneficial Ownership
Chief Legal Officer Nathaniel Sisitsky was granted 73,435 restricted stock units and 73,434 stock options by QuidelOrtho Corp.
Summary
- Nathaniel Sisitsky, Chief Legal Officer of QuidelOrtho Corp, received a new equity compensation package on April 15, 2026.
- The grant includes 73,435 restricted stock units (RSUs) and 73,434 non-qualified stock options.
- The stock options have an exercise price of $17.49 per share.
- The RSUs vest in three annual installments starting April 15, 2027, with the final portion vesting on April 15, 2029.
- The stock options vest in three equal annual installments beginning April 15, 2027, and expire on April 15, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which is expected in the normal course of business.
Positives
- Equity-based compensation aligns the interests of the Chief Legal Officer with long-term shareholder value.
- The multi-year vesting schedule encourages executive retention.
Negatives
- The issuance of new equity awards results in potential future dilution for existing shareholders.
Risks
- The value of the granted equity is subject to market volatility and the future performance of QuidelOrtho common stock.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a standard disclosure of executive equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to C-suite executives are standard corporate governance practices intended to incentivize long-term performance and align leadership with shareholder interests.
Comparison to Industry Standards
- The use of multi-year vesting schedules (3-year) is consistent with standard executive compensation practices in the healthcare and diagnostics sector.
- Granting a mix of RSUs and stock options is a common strategy to balance risk and reward for senior management.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise and vesting of these equity instruments.
Next Steps
- Vesting of equity awards beginning April 15, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/15/2026 | Date of the equity grant transaction. |
| 04/15/2027 | First vesting date for both RSUs and stock options. |
| 04/15/2028 | Second vesting date for RSUs and stock options. |
| 04/15/2029 | Final vesting date for RSUs and stock options. |
| 04/15/2036 | Expiration date for the non-qualified stock options. |
Keywords
QuidelOrtho, QDEL, Insider Trading, Form 4, Executive Compensation, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.